Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
With a slashed valuation the newly listed biotech heads for phase 3.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
An actinium-based backup and Werner helicase inhibitor are notable absences.
But the Astra/Daiichi ADC stumbles in lung cancer.
